A5044522767- Prostate Cancer Treatment and Research
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
- Cancer and Skin Lesions
- Soft tissue tumor case studies
- Lymphoma Diagnosis and Treatment
- Urologic and reproductive health conditions
- Radiopharmaceutical Chemistry and Applications
- Heat shock proteins research
- Viral Infectious Diseases and Gene Expression in Insects
- Cytokine Signaling Pathways and Interactions
- Prostate Cancer Diagnosis and Treatment
- HIV/AIDS drug development and treatment
- Cancer-related gene regulation
- Epigenetics and DNA Methylation
- Acute Myeloid Leukemia Research
- Cancer, Hypoxia, and Metabolism
- RNA Research and Splicing
Weill Cornell Medicine
2016-2022
Cornell University
2016-2022
Lander Institute
2018-2022
Texas Health Dallas
2021
Abstract The epichaperome is a new cancer target composed of hyperconnected networks chaperome members that facilitate cell survival. Cancers with an altered chaperone configuration may be susceptible to inhibitors. We developed flow cytometry-based assay for evaluation and monitoring abundance at the single level, goal prospectively identifying patients likely respond inhibitors, measure engagement, dependency during treatment. As proof principle, we describe patient unclassified...
BACKGROUNDProstate cancer is multifocal with distinct molecular subtypes. The utility of genomic subtyping has been challenged due to inter- and intrafocal heterogeneity. We sought characterize the subtype-defining alterations primary prostate across all tumor foci within radical prostatectomy (RP) specimens determine prevalence collision tumors.METHODSFrom Early Detection Research Network cohort, we identified 333 prospectively collected RPs from 2010 2014 assessed ETS-related gene (ERG),...
Abstract Emerging observations from clinical trials suggest that a subset of castration resistant prostate adenocarcinomas (CRPC) eventually evolve or progress to predominantly neuroendocrine phenotype (NEPC). This transition is emerging as an important mechanism treatment resistance. cell plasticity characterized by loss androgen receptor (AR) and specific antigen (PSA), significant over-expression gene amplification MYCN (encoding N-Myc). While N-Myc bona fide driver oncogene in several...